İnfertilitede Gen Tedavisi ve Etik Kaygılar
Özet
Gen tedavisi, kalıtsal ve tedavi edilemeyen hastalıkların iyileştirilmesi amacıyla organizmaya transgen adı verilen genetik materyalin aktarılması sürecidir. Bu yöntem, kalıtımsal olarak taşınmayan somatik hücre tedavisi ve sperm ile oositlere uygulanıp kalıtımsal değişikliklere yol açan germ hücre tedavisi olmak üzere ikiye ayrılır. İnfertilite (kısırlık) tedavisinde yardımcı üreme tekniklerinin yetersiz kaldığı durumlarda sperm, testis, kök hücre ve mitokondriyal gen tedavileri önemli birer seçenek olarak değerlendirilmektedir. Gen transferinde yüksek verimliliğe sahip retrovirüs, lentivirüs, adenovirüs ve adeno-assosiye virüsler gibi viral vektörlerin yanı sıra mikroenjeksiyon, elektroporasyon ve lipozomlar gibi viral olmayan fiziksel ve kimyasal yöntemler kullanılmaktadır. Son yıllarda öne çıkan CRISPR-Cas9 sistemi ise ekonomikliği, yüksek spesifitesi ve çok yönlülüğü ile gen düzenlemede çığır açmıştır. Ancak gen tedavileri, özellikle germ hücre manipülasyonları ve in utero uygulamalar, hedef dışı mutasyon riskleri, öngörülemeyen kalıtsal etkiler, rıza dışı müdahale ve "sipariş bebek" üretimi gibi ciddi etik kaygıları ve tartışmaları beraberinde getirmektedir. Sonuç olarak, gen transfer teknolojilerinin kontrollü ve bilinçli şekilde geliştirilmesi, etik kaygıları aşarak kısırlık dahil pek çok hastalığın tedavisinde büyük bir umut kaynağı vaat etmektedir.
Gene therapy is the process of transferring genetic material, called transgene, into an organism to treat or clinically improve hereditary and incurable diseases. This method is divided into somatic cell therapy, which is not heritable, and germ cell therapy, which is applied to sperm or oocytes and causes heritable changes. In infertility treatments where assisted reproductive techniques fall short, sperm-mediated, testis-mediated, stem cell, and mitochondrial gene therapies are considered significant alternatives. For gene transfer, viral vectors with high transduction efficiency such as retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses are used, alongside non-viral physical and chemical methods like microinjection, electroporation, and liposomes. The CRISPR-Cas9 system, which has become prominent in recent years, has revolutionized genome editing due to its cost-effectiveness, high specificity, and versatility. However, gene therapies, particularly germline manipulations and in utero applications, bring about severe ethical concerns and debates, including off-target mutation risks, unpredictable hereditary effects, interventions without prior consent, and the commercialized creation of "designer babies". Consequently, the conscious and controlled development of gene transfer technologies holds great promise for elucidating and treating many diseases, including infertility, provided that off-target damages and ethical concerns are resolved.
Referanslar
Samsunlu, E.T. Gen Terapisinde CRISPR-Cas9. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi; 8(3); 574-580.
Yatsenko, S.A. and A. Rajkovic. Genetics of human female infertilitydagger. Biol Reprod, 2019; 101(3); 549-566. DOI: 10.1093/biolre/ioz084.
Tuke, M.A., K.S. Ruth, A.R. Wood, et al. Mosaic Turner syndrome shows reduced penetrance in an adult population study. Genet Med, 2019; 21(4); 877-886. DOI: 10.1038/s41436-018-0271-6.
Abir, R., B. Fisch, R. Nahum, et al. Turner's syndrome and fertility: current status and possible putative prospects. Hum Reprod Update, 2001; 7(6); 603-10. DOI: 10.1093/humupd/7.6.603.
Griffin, D.K. and K.A. Finch. The genetic and cytogenetic basis of male infertility. Hum Fertil (Camb), 2005; 8(1); 19-26. DOI: 10.1080/14647270400016407.
Affara, N.A. and M.J. Mitchell. The role of human and mouse Y chromosome genes in male infertility. J Endocrinol Invest, 2000; 23(10); 630-45. DOI: 10.1007/BF03343787.
Rashnonejad, A., B. Durmaz and F. Özkınay. Gen tedavisinin temel ilkeleri ve son gelişmeler. Ege Tıp Dergisi, 2014; 53(4); 231-240.
Cellini, F., A. Chesson, I. Colquhoun, et al. Unintended effects and their detection in genetically modified crops. Food Chem Toxicol, 2004; 42(7); 1089-125. DOI: 10.1016/j.fct.2004.02.003.
Haritha, P.N., S. Uma, D.P. Nagaratna, et al. Gene Therapy–A review. Int J Biopharm, 2012; 3; 55-64.
Razi Soofiyani, S., B. Baradaran, F. Lotfipour, et al. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull, 2013; 3(2); 249-55. DOI: 10.5681/apb.2013.041.
Kay, M.A., J.C. Glorioso and L. Naldini. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med, 2001; 7(1); 33-40. DOI: 10.1038/83324.
Palanki, R., W.H. Peranteau and M.J. Mitchell. Delivery technologies for in utero gene therapy. Adv Drug Deliv Rev, 2021; 169; 51-62. DOI: 10.1016/j.addr.2020.11.002.
Kindy, M.S., J. Yu, H. Zhu, et al. A therapeutic cancer vaccine against GL261 murine glioma. J Transl Med, 2016; 14; 1. DOI: 10.1186/s12967-015-0757-9.
Giacca, M. and S. Zacchigna. Virus-mediated gene delivery for human gene therapy. J Control Release, 2012; 161(2); 377-88. DOI: 10.1016/j.jconrel.2012.04.008.
Kars, A. Gen tedavisi. XIII. TPOG Ulusal Pediatrik Kanser Kongresi, Non-Hongkin Lenfoma, 2004; 18-22.
Daftary, G.S. and H.S. Taylor. Reproductive tract gene transfer. Fertil Steril, 2003; 80(3); 475-84. DOI: 10.1016/s0015-0282(03)00970-1.
Wu, S.G., W.W. Zhang, J. Wang, et al. 21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery. Front Oncol, 2019; 9; 1. DOI: 10.3389/fonc.2019.00001.
Wang, D. and G. Gao. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med, 2014; 18(97); 67-77.
Lee, C.S., E.S. Bishop, R. Zhang, et al. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis, 2017; 4(2); 43-63. DOI: 10.1016/j.gendis.2017.04.001.
Li, C. and R.J. Samulski. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet, 2020; 21(4); 255-272. DOI: 10.1038/s41576-019-0205-4.
Attar, A. Gen terapi yöntemleri: Fiziksel ve kimyasal metodlar. Türk Hijyen ve Deneysel Biyoloji Dergisi; 74(1); 103-112.
Yang, N.S. and W.H. Sun. Gene gun and other non-viral approaches for cancer gene therapy. Nat Med, 1995; 1(5); 481-3. DOI: 10.1038/nm0595-481.
Keefer, C.L. Production of bioproducts through the use of transgenic animal models. Anim Reprod Sci, 2004; 82-83; 5-12. DOI: 10.1016/j.anireprosci.2004.04.010.
Ekici, A., M. Timur and H. Bağış. Transgenik Canlılar ve Akuakültürdeki Önemi. Ege Journal of Fisheries and Aquatic Sciences, 2006; 23(2); 211-214.
Schmidt-Wolf, G.D. and I.G. Schmidt-Wolf. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med, 2003; 9(2); 67-72. DOI: 10.1016/s1471-4914(03)00005-4.
Özcan, A.G. Gen tedavisi ve biyogüvenlik. Türk Hijyen ve Deneysel Biyoloji Dergisi, 2007; 64(1); 35-50.
Nasr-Esfahani, M.H., M.R. Deemeh and M. Tavalaee. Artificial oocyte activation and intracytoplasmic sperm injection. Fertil Steril, 2010; 94(2); 520-6. DOI: 10.1016/j.fertnstert.2009.03.061.
Shastry, B.S. Gene disruption in mice: models of development and disease. Mol Cell Biochem, 1998; 181(1-2); 163-79. DOI: 10.1023/a:1006865210012.
Brackett, B.G., W. Baranska, W. Sawicki, et al. Uptake of heterologous genome by mammalian spermatozoa and its transfer to ova through fertilization. Proc Natl Acad Sci U S A, 1971; 68(2); 353-7. DOI: 10.1073/pnas.68.2.353.
Lavitrano, M., A. Camaioni, V.M. Fazio, et al. Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice. Cell, 1989; 57(5); 717-23. DOI: 10.1016/0092-8674(89)90787-3.
Lavitrano, M., B. Maione, E. Forte, et al. The interaction of sperm cells with exogenous DNA: a role of CD4 and major histocompatibility complex class II molecules. Exp Cell Res, 1997; 233(1); 56-62. DOI: 10.1006/excr.1997.3534.
Zani, M., M. Lavitrano, D. French, et al. The mechanism of binding of exogenous DNA to sperm cells: factors controlling the DNA uptake. Exp Cell Res, 1995; 217(1); 57-64. DOI: 10.1006/excr.1995.1063.
Parrington, J., K. Coward and J. Gadea. Sperm and testis mediated DNA transfer as a means of gene therapy. Syst Biol Reprod Med, 2011; 57(1-2); 35-42. DOI: 10.3109/19396368.2010.514022.
Sato, M. Testis-mediated gene transfer (TMGT) in mice: Successful transmission of introduced DNA from F0 to F2 generations. Transgenics, 1999; 3; 11-22.
Ogawa, S., K. Hayashi, N. Tada, et al. Gene expression in blastocysts following direct injection of DNA into testis. Journal of Reproduction and Development, 1995; 41(4); 379-382.
Chang, K.-T., A. Ikeda, K. Hayashi, et al. Production of transgenic rats and mice by the testis-mediated gene transfer. Journal of Reproduction and Development, 1999; 45(1); 29-36.
Toyooka, Y., N. Tsunekawa, R. Akasu, et al. Embryonic stem cells can form germ cells in vitro. Proc Natl Acad Sci U S A, 2003; 100(20); 11457-62. DOI: 10.1073/pnas.1932826100.
Hajiesmailpoor, A., P. Emami, B.J. Kondori, et al. Stem cell therapy as a recent advanced approach in male infertility. Tissue Cell, 2021; 73; 101634. DOI: 10.1016/j.tice.2021.101634.
Aydos, K. İnfertil erkeklerde kök hücre tedavisi. Androloji Bülteni; 18(65); 130-133.
Peranteau, W.H. and A.W. Flake. The Future of In Utero Gene Therapy. Mol Diagn Ther, 2020; 24(2); 135-142. DOI: 10.1007/s40291-020-00445-y.
Bose, S.K., P. Menon and W.H. Peranteau. InUtero Gene Therapy: Progress and Challenges. Trends Mol Med, 2021; 27(8); 728-730. DOI: 10.1016/j.molmed.2021.05.007.
Almeida-Porada, G., S.N. Waddington, J.K.Y. Chan, et al. In Utero Gene Therapy Consensus Statement from the IFeTIS. Mol Ther, 2019; 27(4); 705-707. DOI: 10.1016/j.ymthe.2019.02.015.
Fu, L., Y.X. Luo, Y. Liu, et al. Potential of Mitochondrial Genome Editing for Human Fertility Health. Front Genet, 2021; 12; 673951. DOI: 10.3389/fgene.2021.673951.
Vaught, R.C. and D.K. Dowling. Maternal inheritance of mitochondria: implications for male fertility? Reproduction, 2018; 155(4); R159-R168. DOI: 10.1530/REP-17-0600.
Sreerangaraja Urs, D.B., W.H. Wu, K. Komrskova, et al. Mitochondrial Function in Modulating Human Granulosa Cell Steroidogenesis and Female Fertility. Int J Mol Sci, 2020; 21(10). DOI: 10.3390/ijms21103592.
Yahata, N., Y. Matsumoto, M. Omi, et al. TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation. Sci Rep, 2017; 7(1); 15557. DOI: 10.1038/s41598-017-15871-y.
Jo, A., S. Ham, G.H. Lee, et al. Efficient Mitochondrial Genome Editing by CRISPR/Cas9. Biomed Res Int, 2015; 2015; 305716. DOI: 10.1155/2015/305716.
Anzalone, A.V., L.W. Koblan and D.R. Liu. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol, 2020; 38(7); 824-844. DOI: 10.1038/s41587-020-0561-9.
Jinek, M., K. Chylinski, I. Fonfara, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337(6096); 816-21. DOI: 10.1126/science.1225829.
Ilıkkan, Ö.K. Laktik Asit Bakterilerinde CRISPR/Cas Sisteminin Biyoteknoloji ve Genetik Mühendisliğinde Kullanımı. Akademik Gıda, 2020; 18(3); 303-311.
Barrangou, R. and L.A. Marraffini. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell, 2014; 54(2); 234-44. DOI: 10.1016/j.molcel.2014.03.011.
Köse, S.B.E., Ü. SURa, A. YİRUN, et al. CRISPR-Cas9 Teknolojisi, Güvenliliği ve Etik Açıdan Değerlendirilmesi. Literatür Eczacılık Bilimleri Dergisi, 2020; 9(1); 50-64.
Barrangou, R., C. Fremaux, H. Deveau, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science, 2007; 315(5819); 1709-12. DOI: 10.1126/science.1138140.
Zhang, X., T. Li, J. Ou, et al. Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing. Protein Cell, 2021. DOI: 10.1007/s13238-021-00838-7.
Mali, P., L. Yang, K.M. Esvelt, et al. RNA-guided human genome engineering via Cas9. Science, 2013; 339(6121); 823-6. DOI: 10.1126/science.1232033.
Suzuki, K., Y. Tsunekawa, R. Hernandez-Benitez, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature, 2016; 540(7631); 144-149. DOI: 10.1038/nature20565.
Young, S.A., H. Miyata, Y. Satouh, et al. CRISPR/Cas9-Mediated Rapid Generation of Multiple Mouse Lines Identified Ccdc63 as Essential for Spermiogenesis. Int J Mol Sci, 2015; 16(10); 24732-50. DOI: 10.3390/ijms161024732.
Abbasi, F., M. Kodani, C. Emori, et al. CRISPR/Cas9-Mediated Genome Editing Reveals Oosp Family Genes are Dispensable for Female Fertility in Mice. Cells, 2020; 9(4). DOI: 10.3390/cells9040821.
Greely, H.T. CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'. J Law Biosci, 2019; 6(1); 111-183. DOI: 10.1093/jlb/lsz010.
Brokowski, C. and M. Adli. CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool. J Mol Biol, 2019; 431(1); 88-101. DOI: 10.1016/j.jmb.2018.05.044.
Yamamoto, T., Targeted Genome Editing Using Site-Specific Nucleases. 2015: Springer.
Doudna, J.A. and E. Charpentier. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014; 346(6213); 1258096. DOI: 10.1126/science.1258096.
